Megapro Biotech’s home-grown enterovirus 71 vaccine has been recognised at the Asian Conference on Paediatric Infectious Diseases for its potential to provide long-lasting immunity in children, with studies showing high safety and efficacy across age groups.
Megapro Biotech said on 17 August that its home-grown enterovirus 71 vaccine has drawn international attention after being selected for oral presentation at the 12th Asian Conference on Paediatric Infectious Diseases in Bandung, Indonesia. The company said the latest findings show the shot continues to generate strong neutralising antibodies for at least six to seven years, with a reported seroprotection rate of 98.2%.
The company also said separate immunogenicity and safety work in children aged six to under 10 produced results similar to those seen in younger children aged from two months to under six years, suggesting the vaccine performs consistently across age groups. Earlier studies of inactivated EV71 vaccines in younger and older children have also reported strong immune responses, high seroconversion rates and good tolerability, while a later phase III trial in children aged 36 to 71 months found the vaccine remained immunogenic and safe.
Enterovirus 71 is one of the main causes of severe hand, foot and mouth disease and can lead to serious complications including encephalitis, myocarditis and pulmonary oedema in infants and young children. Research published in recent years has also suggested that EV71 vaccines can maintain antibody levels for years after immunisation, and that some formulations can be given safely alongside routine influenza vaccination without reducing the immune response to either shot.
For parents, the practical message is that the protection these vaccines are designed to offer appears to be both durable and well tolerated, at least in the studies cited by the company and in the wider published literature. Megapro Biotech said the conference invitation reflects international recognition of the scientific quality of its work, though the findings will need to be judged alongside broader clinical and regulatory evidence.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
